Betta Pharmaceuticals (300558.SZ): BPI-452080 tablet drug clinical trial application accepted.

Betta Pharmaceuticals (300558.SZ) announced that today, the company has received the "Notice of Acceptance" (Acceptance No.: CXHL2401263, CXHL2401264, CXHL2401265) issued by the National Medical Products Administration (NMPA). The company's application for the clinical trial of BPI-452080 tablets (referred to as "the clinical trial") has been accepted by the NMPA. It is reported that BPI-452080 is a new molecular entity compound independently developed by the company with full independent intellectual property rights. It is an innovative, orally available small molecule HIF-2 (Hypoxia Inducible Factor-2alpha) inhibitor intended for use in von Hippel-Lindau (VHL) syndrome-related tumors and solid tumors (including but not limited to renal cancer, pancreatic neuroendocrine tumors, paraganglioma/pheochromocytoma, etc.).